Naotaka Kuroda

Prof. Dr. Naotaka Kuroda

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2004 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
YSYen Sun
Yen Sun
MIMiki Irie
Miki Irie
Naoya KishikawaNaoya Kishikawa
Naoya Kishikawa
MWMitsuhiro Wada
Mitsuhiro Wada
NKNaotaka Kuroda
Naotaka Kuroda
KNKenichiro Nakashima
Kenichiro Nakashima

1 January 2003 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
NKNaotaka Kuroda
Naotaka Kuroda
YKYumi Kinoshita
Yumi Kinoshita
YSYen Sun
Yen Sun
MWMitsuhiro Wada
Mitsuhiro Wada
Naoya KishikawaNaoya Kishikawa
Naoya Kishikawa
HNHiroyuki Nakazawa
Hiroyuki Nakazawa

1 June 2003 in Journal of Chromatography B
Verified
Journal Article
Closed access
Naoya KishikawaNaoya Kishikawa
Naoya Kishikawa
MWMitsuhiro Wada
Mitsuhiro Wada
NKNaotaka Kuroda
Naotaka Kuroda
SASyuzo Akiyama
Syuzo Akiyama
KNKenichiro Nakashima
Kenichiro Nakashima

1 February 1995 in Analytica Chimica Acta
Verified
Journal Article
Closed access
KNKenichiro Nakashima
Kenichiro Nakashima
HYHiromi Yamasaki
Hiromi Yamasaki
NKNaotaka Kuroda
Naotaka Kuroda
SAShuzo Akiyama
Shuzo Akiyama

15 April 2009 in Talanta
Verified
Journal Article
Closed access
ٍAٍSAMEH ABDELRAOUF AHMED
ٍSAMEH ABDELRAOUF AHMED
Naoya KishikawaNaoya Kishikawa
Naoya Kishikawa
KOK Ohyama
K Ohyama
MWM Wada
M Wada
KNK Nakashima
K Nakashima
NKNaotaka Kuroda
Naotaka Kuroda

1 June 2011 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
KOKaname Ohyama
Kaname Ohyama
YUYukitaka Ueki
Yukitaka Ueki
AKAtsushi Kawakami
Atsushi Kawakami
Naoya KishikawaNaoya Kishikawa
Naoya Kishikawa
MTMami Tamai
Mami Tamai
NKNaotaka Kuroda
Naotaka Kuroda
BACKGROUND: Analysis of circulating immune complexes (CICs) produced during an immune response may be useful in elucidating some aspects of this process. Identification of antigens incorporated into CICs provides information that may be helpful in developing diagnostic and treatment strategies for autoimmune diseases, infection, cancer, and transplantation therapy, and such information might be more relevant than information on free antigens. Because CICs may contain many antigens, comprehensive identification and profiling of such antigens is more effective than immunoblotting detection. METHODS: We developed a novel proteomic strategy (immune complexome analysis) in which immune complexes (ICs) are separated from serum, digested directly with trypsin, and then subjected to nano-liquid chromatography–tandem mass spectrometry for identifying and profiling antigens in CICs. We applied this strategy to the analysis of CICs in 21 rheumatoid arthritis (RA) patients. Serum samples from 13 healthy donors and 8 osteoarthritis patients were used as controls. RESULTS: CICs containing thrombospondin-1 (TSP-1) and platelet factor 4 (PF4) were found in the serum of 81% and 52% of RA patients, respectively, and in none of the controls. CONCLUSIONS: The ICs in the serum of a majority of the RA patients contained TSP-1 or PF4, and these ICs may have potential as alternative biomarkers. Our technique for immune complexome analysis uses routine clinical samples, simple protocols, and widely available equipment. This method may be generally applicable to the study of the relationship between CICs and certain diseases associated with the immune response in animals and humans.